Antibacterial, antibiofilm, mucus penetration properties and pulmonary biocompatibility of inhalable spray-dried levofloxacin–ambroxol composite microparticles
European Journal of Pharmaceutics and Biopharmaceutics · 2026-11 · 115295
DOI: 10.1016/j.ejpb.2026.115295 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026-11. Verfasst von Ruwani K Suraweera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Discipline, School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia; Centre for I…. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study evaluated the antibacterial and biofilm-disruption activities of spray-dried levofloxacin (LVX) and ambroxol (AMB) composite dry powder inhaler (DPI) formulations against laboratory and clinical strains of P. aeruginosa and a clinical S. aureus strain. Cytotoxicity and pro-inflammatory activity of the formulations were investigated in THP-1 derived macrophages, healthy and COPD bronchial epithelial cells (HBE), and mucus penetration using an artificial mucus model. Spray dried LVX retained antibacterial activity against PA14 (MIC50 0.075-0.099 µg/mL versus 0.076 µg/mL for free LVX), whereas free AMB showed no antibacterial activity. Formulations containing higher AMB proportions, exhibited greater antibacterial activity than free LVX against AUST-02 and 2.1. The developed formulations also enhanced biofilm disruption against PA14 and AUST-02. AMB improved penetration of spray-dried LVX, particularly with F4 (LVX:AMB 1:1 with 5 % leucine) showing statistically significant (p 83 %) in THP-1 macrophages, while no significant cytotoxicity or increase in IL-8 production was observed. Overall, the prepared composite antibiotic microparticles demonstrated superior antibacterial activity against the tested clinical strains, enhanced biofilm disruption and LVX mucus penetration, while preserving pulmonary biocompatibility in the tested cell models.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacy Discipline, School of Clinical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia; Centre for Immunology and Infection Control (CIIC), Faculty of Health, Queensland…
- Frazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
- Centre for Immunology and Infection Control (CIIC), Faculty of Health, Queensland University of Technology, Brisbane, QLD 4000, Australia.
- School of Biomedical Sciences, The University of Queensland, St Lucia, QLD 4067, Australia.
- School of Chemistry & Physics, Faculty of Science, Queensland University of Technology, Brisbane, QLD 4000, Australia.
Zitieren
APA
Suraweera, R. K., Panthi, V. K., Hickson, S. M., Yarlagadda, T., Burow, R., Kiriakous, E., Wells, T. J., Kaminskas, L. M., Spann, K. M., & Islam, N. (2026). Antibacterial, antibiofilm, mucus penetration properties and pulmonary biocompatibility of inhalable spray-dried levofloxacin–ambroxol composite microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 115295. https://doi.org/10.1016/j.ejpb.2026.115295
Vancouver
Suraweera RK, Panthi VK, Hickson SM, Yarlagadda T, Burow R, Kiriakous E, et al. Antibacterial, antibiofilm, mucus penetration properties and pulmonary biocompatibility of inhalable spray-dried levofloxacin–ambroxol composite microparticles. European Journal of Pharmaceutics and Biopharmaceutics. 2026:115295. doi:10.1016/j.ejpb.2026.115295
BibTeX
@article{Suraweera2026,
author = {Suraweera, Ruwani K and Panthi, Vijay Kumar and Hickson, Sarah M and Yarlagadda, Tejasri and Burow, Rachel and Kiriakous, Emad and Wells, Timothy J and Kaminskas, Lisa M and Spann, Kirsten M and Islam, Nazrul},
title = {Antibacterial, antibiofilm, mucus penetration properties and pulmonary biocompatibility of inhalable spray-dried levofloxacin–ambroxol composite microparticles},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2026},
pages = {115295},
doi = {10.1016/j.ejpb.2026.115295}
}
EUVIMED